|
Baseline characteristics from a retrospective, observational, US-based, multicenter, real-world (RW) study of avelumab first-line maintenance (1LM) in locally advanced/metastatic urothelial carcinoma (la/mUC) (PATRIOT-II). |
|
|
Consulting or Advisory Role - 4D Pharma; Astellas Pharma; AstraZeneca; BostonGene; Bristol-Myers Squibb; Dyania Health; EMD Serono; Exelixis; Fresenius Kabi; G1 Therapeutics; Genentech; Gilead Sciences; Guardant Health; Infinity Pharmaceuticals; Janssen; Lucence; Merck; Mirati Therapeutics; Pfizer; PureTech; QED Therapeutics; Regeneron; Roche; Seagen; Silverback Therapeutics; Urogen pharma |
Research Funding - Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Merck (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); QED Therapeutics (Inst) |
|
|
Consulting or Advisory Role - AstraZeneca; AVEO; Bayer; BMS; Caris Life Sciences; Dendreon (Inst); Eisai; EMD Serono; Exelixis; Pfizer |
Speakers' Bureau - Bayer (Inst); Caris Life Sciences (Inst); Pfizer/Astellas (Inst) |
Research Funding - AVEO (Inst); Blue Earth Diagnostics (Inst); Merck (Inst); Pfizer (Inst) |
|
|
Honoraria - EMD Serono; Pfizer/EMD Serono |
Research Funding - Amgen (Inst); Apollomics (Inst); Arcus Biosciences (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); HUYA Bioscience International (Inst); Nektar (Inst); Prometheus; Revimmune (Inst); Revimmune (Inst); Revimmune (Inst); Seagen (Inst) |
|
|
Employment - Texas Oncology |
Honoraria - Astellas Pharma; Bayer/Onyx; Bristol-Myers Squibb; Eisai; Exelixis; Johnson & Johnson; Novartis; Pfizer |
Consulting or Advisory Role - Astellas Pharma; Bayer/Onyx; Bristol-Myers Squibb; Eisai; Exelixis; Johnson & Johnson; Novartis; Pfizer |
Speakers' Bureau - Astellas Pharma; Bristol-Myers Squibb; Eisai; Exelixis; Johnson & Johnson; Pfizer |
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Johnson & Johnson (Inst); Pfizer (Inst) |
|
|
Stock and Other Ownership Interests - Moderna Therapeutics; Nektar |
Honoraria - Bristol-Myers Squibb |
Consulting or Advisory Role - AVEO; EMD Serono; Gilead Sciences; Guardant Health; Loxo/Lilly; Merck; Pfizer |
Speakers' Bureau - Bristol-Myers Squibb; Janssen Oncology |
|
|
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb/Medarex; Foundation Medicine; Genzyme; Immunomedics; IMPAC Medical Systems; Incyte; Medscape; Merck; MSD; Pfizer; Roche; UroToday |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - AbbVie; Bristol-Myers Squibb; EPI-Q; Johnson & Johnson |
Research Funding - Acceleron Pharma; Amolyt Pharma; Bristol-Myers Squibb; ChemoCentryx; EMD Serono; Janssen; Neurocrine Biosciences; Pfizer; United Therapeutics |
|
|
|
Stock and Other Ownership Interests - Pfizer |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Pfizer |
Research Funding - Pfizer |
Travel, Accommodations, Expenses - Pfizer |
|
|
|
|
|
|
Stock and Other Ownership Interests - EMD Serono |
Travel, Accommodations, Expenses - Merck KGaA |
|
|
|
Stock and Other Ownership Interests - Merck KGaA |
|
|
|
Speakers' Bureau - EMD Serono |
Research Funding - Bicycle Therapeutics (Inst); Jounce Therapeutics (Inst); Merck (Inst); Novita Pharmaceuticals (Inst); Seagen (Inst) |
|
|
Employment - Myriad Genetics (I) |
|
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bicycle Therapeutics; Bristol-Myers Squibb; Eisai; EMD Serono; Exelixis; G1 Therapeutics; Genentech; Gilead Sciences; Infinity Pharmaceuticals; Janssen; Loxo/Lilly; Merck; Pfizer; Scholar Rock; Seagen |
Speakers' Bureau - Medscape; Onclive; Physicans' Education Resource; Research to Practice |
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Gilead Sciences (Inst); Janssen (Inst); Predicine (Inst); QED Therapeutics (Inst); Sanofi (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
Other Relationship - Astellas Pharma; AstraZeneca; Bavarian Nordic; Bristol-Myers Squibb; Debiopharm Group; Elsevier; G1 Therapeutics; Mereo BioPharma; QED Therapeutics |